Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT

Annalisa Ruggeri, Myriam Labopin, Andrea Bacigalupo, Boris Afanasyev, Jan J. Cornelissen, Ahmet Elmaagacli, Maija Itala-Remes, Didier Blaise, Ellen Meijer, Yener Koc, Noel Milpied, Harry C. Schouten, Nicolaus Kroeger, Mohamad Mohty, Arnon Nagler

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number40
Number of pages10
JournalJournal of Hematology & Oncology
Volume11
DOIs
Publication statusPublished - 15 Mar 2018

Keywords

  • Hematopoietic stem cell transplantation
  • Post-transplantation cyclophosphamide
  • Stem cell source
  • Acute leukemia
  • Acute graft-versus-host disease
  • BONE-MARROW-TRANSPLANTATION
  • HEMATOPOIETIC-CELL TRANSPLANTATION
  • HIGH-DOSE CYCLOPHOSPHAMIDE
  • SINGLE-AGENT
  • HEMATOLOGIC MALIGNANCIES
  • MYCOPHENOLATE-MOFETIL
  • GVHD PROPHYLAXIS
  • PHASE-II
  • SURVIVAL
  • METHOTREXATE

Cite this

Ruggeri, A., Labopin, M., Bacigalupo, A., Afanasyev, B., Cornelissen, J. J., Elmaagacli, A., Itala-Remes, M., Blaise, D., Meijer, E., Koc, Y., Milpied, N., Schouten, H. C., Kroeger, N., Mohty, M., & Nagler, A. (2018). Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. Journal of Hematology & Oncology, 11, [40]. https://doi.org/10.1186/s13045-018-0586-4